News & Events

Corporate Presentation

Corporate Presentation - May 2019

News Releases

Year

Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting

May 16, 2019

NEW YORK , May 16, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp) clinical data in chronic myelomonocytic

Additional Formats

PDF Version

Stemline Therapeutics Reports First Quarter 2019 Financial Results

May 10, 2019

Net revenue for ELZONRIS was $5.05 million for the first quarter Conference call and live webcast scheduled for today at 8:00 AM ET NEW YORK , May 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and

Additional Formats

PDF Version

Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019

May 8, 2019

NEW YORK , May 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company will host a conference call and live webcast on

Additional Formats

PDF Version

Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results

April 25, 2019

NEW YORK , April 25, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the pivotal trial results of ELZONRIS™ (tagraxofusp), a

Additional Formats

PDF Version

Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference

March 18, 2019

NEW YORK , March 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that Ivan Bergstein , M.D., Stemline’s CEO, was selected to

Additional Formats

PDF Version